• Product Development Will Go Digital To Speed Medicines To Patients

    While COVID-19 brought great chaos and crises last year, it also fueled incredible innovation and collaboration across the life sciences industry. Learn how digital acceleration will reinvent the clinical trial landscape in 2021.

  • Ask An Expert: TMF Management Community Q&A

    Watch TMF experts Gillian Gittens and Laurel-Ann Schrader answer clients' questions on all things related to TMF management, including topics like relevant communications, TMF archiving, and best practices to avoid inspection findings.

  • Best Practice For Using Technology And AI To Manage The End-to-End Medical Information Content Lifecycle

    The abundance of new channels and the pressure to provide quality information to their customers faster is a challenge for any company. When you add on the requirement to do this in other languages, paired with budgetary restrictions in our current climate, this can be even more daunting. Here are some ways to bring efficiencies to your medical information (MI) content processes immediately while ensuring better and faster content delivery for customers.

  • Parameters For IRB Review And Approval Of Electronic Consent Documents

    There are an increasing number of internet-based and electronic tools to assist in the conduct of research studies, but how do you ensure the format you’re delivering to patients clearly explains study changes and new procedures? Now, more than ever, there is a focused need on the design, conduct, and ethical challenges of trials involving eConsent platforms.

  • Can Your eClinical Empower Patients And Inform Stakeholders?

    Explore how your eClinical can become a powerful tool for patient engagement that yields high-quality outcomes.

  • 4 Questions To Ask CTMS Vendors

    Here are four questions to ask during the vendor selection process to offer more insight into your future success with the selected vendor.

  • Mixed-Modality Deployment Compatible With Any Trial Design

    The needs of the clinical trial protocol — not the limitations of technology — should determine how a study is deployed. That said, until now, data collection technology has constrained data collection and review. To achieve a flexible, patient-driven design, we needed to make our system even more powerful and adaptable.

  • PerkinElmer Solution For Clinical Study Data Review Used Across All Therapeutic Areas And All Phases Of Clinical Trials

    Top 10 global biopharmaceutical company needed to implement a single clinical study data review system to reduce the time, cost and risk of running their clinical trials while accelerating the time to market. The company deployed PerkinElmer's interactive data visualization and analysis solution to their clinicians and safety reviewers as part of a safety review tool that is quickly becoming the tool of choice for clinical data review.

  • 5 Signs Your EDC Takes Data Security Seriously

    Patient data has become more valuable and vulnerable as the technology used to store it – EDC, EHRs, and other systems – outpaces the regulations designed to protect it. Having a fully compliant, robust EDC is essential to ensuring that regardless of how you facilitate your trial, your data is always accurate, compliant, and secure. Here are some guiding principles to ensure data security for EDC software.


  • Flexible consent technology improves participant comprehension and process oversight. Medrio’s Consent solution empowers organizations to accelerate all aspects of the consent process, from setting up and modifying forms to ensuring patient comprehension, while remaining in full regulatory compliance.

  • The unified Medidata Clinical Cloud™ is an ideal platform to optimize the setup and execution of repeating cycles and visits. You can reduce the effort spent configuring visits in Rave EDC and Rave RTSM by defining visit cycles to support studies with a single, or repeating visit series over fixed or indefinite time periods, in both Rave EDC and Rave RTSM. Rave RTSM supports studies with repeating visit cycles, such as in oncology trials by reducing study complexity, set up time, and human error.

  • Read how IQVIA Biotech can help develop a strategy that will effectively translate into trial execution and avoid costly amendments down the road.

  • PhlexxEVMPD is designed to support the collection, reporting, coding and evaluation of your medicinal product data in a standardized and structured way. Compliant with Article 57, PhlexxEVMPD is a great and easy way to start managing and owning more and more of your data in a digitalized fash

  • Are you submitting study data to the FDA and need a solution that will comply with regulatory requirements? Streamline data collection, management and compliance with Advarra EDC.